16:52 , Apr 13, 2018 |  BC Week In Review  |  Company News

Veracyte, Loxo team up for TRK, RET targeted therapies

Molecular diagnostics company Veracyte Inc. (NASDAQ:VCYT) said Loxo Oncology Inc. (NASDAQ:LOXO) will use Veracyte's Afirma Xpression Atlas platform to develop targeted therapies for thyroid cancers with tropomyosin receptor kinase (TRK) fusions and Ret proto-oncogene (RET)...
15:00 , Jun 2, 2017 |  BC Week In Review  |  Company News

Anthem to cover Veracyte's Afirma test for detecting thyroid cancer

Veracyte Inc. (NASDAQ:VCYT) said Anthem Inc. (NYSE:ANTM) issued a positive coverage decision for Afirma Gene Expression Classifier for thyroid cancer diagnosis. Afirma is a preoperative molecular diagnostic classifier based on genomic measurements from fine needle...
07:00 , Aug 10, 2015 |  BC Week In Review  |  Company News

Veracyte, Aetna sales and marketing update

Veracyte said it will become part of Aetna’s laboratory network. Veracyte administers Afirma, a preoperative molecular diagnostic classifier based on genomic measurements from fine needle aspirate (FNA) samples, to aid in identifying benign tumors...
08:00 , Dec 15, 2014 |  BC Week In Review  |  Company News

Veracyte sales and marketing update

Veracyte said Blue Shield of California issued positive coverage decisions for Afirma Gene Expression Classifier. Afirma is a preoperative molecular diagnostic classifier based on genomic measurements from fine needle aspirate (FNA) samples to...
07:00 , Jul 21, 2014 |  BC Week In Review  |  Company News

Veracyte sales and marketing update

Veracyte said Highmark Inc. and Horizon Blue Cross Blue Shield of New Jersey, both affiliates of Blue Cross Blue Shield, issued positive coverage decisions for Veracyte’s Afirma Gene Expression Classifier. The company markets the...
07:00 , Jun 2, 2014 |  BC Week In Review  |  Company News

Veracyte sales and marketing update

Veracyte launched Afirma Malignancy Classifiers in the U.S. to provide preoperative information to help guide surgical strategy in patients with thyroid nodules. Afirma Malignancy Classifiers comprises genomic tests to identify medullary thyroid cancer (MTC)...
07:00 , May 12, 2014 |  BC Week In Review  |  Company News

Fleury Medicina e Saude, Veracyte, Sanofi sales and marketing update

Veracyte granted Fleury exclusive rights in Brazil to offer Veracyte's Afirma Gene Expression Classifier when patient's thyroid nodule fine needle aspiration (FNA) samples are indeterminate. Veracyte said its worldwide, co-promotion partner, Sanofi's Genzyme...
08:00 , Jan 6, 2014 |  BC Week In Review  |  Company News

Veracyte sales and marketing update

On Dec. 16, 2013, Veracyte said health insurer Cigna issued a positive coverage policy for Veracyte's Afirma Gene Expression Classifier. The new coverage policy, which is effective immediately, will apply to Cigna's 13 million...
08:00 , Nov 4, 2013 |  BioCentury  |  Finance

Highlights of weekly biotech stock moves

Regulatory milestones Amarin Corp. plc (NASDAQ:AMRN) fell $0.54 (25%) to $1.64 last week after disclosing that FDA said it no longer considers a change in serum triglyceride levels sufficient to "establish the effectiveness" of a compound...
00:25 , Oct 31, 2013 |  BC Extra  |  Financial News

Veracyte raises $65 million in IPO

Veracyte Inc. (NASDAQ:VCYT) raised $65 million through the sale of 5 million shares at $13 in an IPO underwritten by Morgan Stanley; Leerink; William Blair; and Cowen. The $13 price values Veracyte at $272.9 million....